DMD and myotonic dystrophy type 1: The development of peptide PMOs (PPMOs) for the treatment of neuromuscular diseases in the groups of Matthew Wood (University of Oxford) and Mike Gait (MRC Laboratory of Molecular Biology, Cambridge) demonstrated the efficacy of this approach treating DM1, DMD and SMA with PMOs conjugated to different CPPs such as Pip6a [35,86,87] (Figure 3).